TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05914922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Tool
Description: 20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
Study: NCT04986644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)
Description: Daily disposable contact lens wear for 1 week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)
Description: Daily disposable contact lens wear for 1 week
Study: NCT05474664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat mesylate
Description: 1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day~2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day
Study: NCT05610410

Intervention type: OTHER
Intervention: Laser speckle contrast analysis
Description: Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT

Intervention type: OTHER
Intervention: Laser speckle contrast analysis
Description: Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
Study: NCT05247853

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Blood collection at enrollment visit

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Blood collection at enrollment visit

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Blood collection at enrollment visit

Intervention type: PROCEDURE
Intervention: Oral, cervicovaginal and anal specimen collection
Description: Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits

Intervention type: PROCEDURE
Intervention: Oral, cervicovaginal and anal specimen collection
Description: Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits

Intervention type: PROCEDURE
Intervention: Oral, cervicovaginal and anal specimen collection
Description: Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits

Intervention type: PROCEDURE
Intervention: Anoscopy & Biopsy of Acetowhite Lesions
Description: Used for management in follow-up visits of persistent anal HPV16/18+ in WLWH

Intervention type: PROCEDURE
Intervention: Anoscopy & Biopsy of Acetowhite Lesions
Description: Used for management in follow-up visits of persistent anal HPV16/18+ in WLWH

Intervention type: PROCEDURE
Intervention: Colposcopy & Biopsy of Acetowhite Lesions
Description: Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV

Intervention type: PROCEDURE
Intervention: Colposcopy & Biopsy of Acetowhite Lesions
Description: Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV

Intervention type: PROCEDURE
Intervention: Colposcopy & Biopsy of Acetowhite Lesions
Description: Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV

Intervention type: PROCEDURE
Intervention: Ablative Treatment
Description: Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy

Intervention type: PROCEDURE
Intervention: Ablative Treatment
Description: Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy

Intervention type: PROCEDURE
Intervention: LEEP (Loop Electrosurgical Excision Procedure)
Description: Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy that ablation ineligible

Intervention type: PROCEDURE
Intervention: LEEP (Loop Electrosurgical Excision Procedure)
Description: Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy that ablation ineligible
Study: NCT06360640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APC148 and Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APC148 and Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APC148 and Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APC148 and Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APC148 and Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APC148 and Placebo
Description: IV infusion
Study: NCT05819827

Intervention type: OTHER
Intervention: Blood and Tissue
Description: Patients will collect stool for microbiome analysis at baseline (i.e., 3 +2 days prior to chemotherapy) and again 5-7 days following initiation of chemotherapy.~Blood samples will be collected prior to their first chemotherapy treatment, and in the second week after chemotherapy.
Study: NCT06403644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTHOR XL Photobiomodulation Full Body Light Bed
Description: Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of \~30 mW/cm\^2.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NovoTHOR XL Photobiomodulation Full Body Light Bed
Description: Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of \~30 mW/cm\^2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARRC LED Photobiomodulation Full Body Light Bed
Description: High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of \~75 mW/cm\^2.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ARRC LED Photobiomodulation Full Body Light Bed
Description: High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of \~75 mW/cm\^2.
Study: NCT04925050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VB0004
Description: Each study part (A,B and C) will be completed sequentially or with partial overlapping. Safety and PK data through at least day 8 from a subsequent cohort will be reviewed by the SMC prior to dosing the fed period of FE cohort. Safety data will be assessed by SMC after completing each cohorts in MAD healthy volunteers and MAD mild Hypertension patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for VB0004
Description: Matching Placebo
Study: NCT05245656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RB/RBAC alternating
Description: Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RB
Description: Every 4 weeks for 6 cycles~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2
Study: NCT04895579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.
Study: NCT05004610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate Solution
Description: continuous intravenous infusion of molar sodium lactate
Study: NCT05310084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline intramuscular injection
Study: NCT05464173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 10-30mg biw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150mg or 100mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrinotherapy（doctor's choice）
Description: According to the drug insert
Study: NCT05748470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinCeuticals A.G.E
Description: Ultrasound therapy combined with SkinCeuticals A.G.E + conventional moisturizing and sunscreen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard cream
Description: Ultrasound therapy combined with standard cream + conventional moisturizing and sunscreen
Study: NCT05298774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-tech WPS
Description: G-tech WPS patches applied and activated within 4 hours of surgery
Study: NCT06142903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 versus 21 medically tailored meals per week
Description: Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 7 versus 21 medically tailored meals per week
Description: Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.
Study: NCT05310084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Inactivated Influenza Vaccine
Description: SIIV intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Inactivated Influenza Vaccine
Description: SIIV intramuscular injection
Study: NCT05787782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo INVSENSOR00063
Description: Masimo INVSENSOR00063 will be used to measure temperature
Study: NCT05499416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16
Study: NCT05740696

Intervention type: PROCEDURE
Intervention: ALF
Description: Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks

Intervention type: PROCEDURE
Intervention: SALF
Description: The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks

Intervention type: PROCEDURE
Intervention: ACLF
Description: On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
Study: NCT05513469

Intervention type: DRUG
Group type: OTHER
Intervention: Lutathera
Description: regulair PRRT of 4 cycles with 7.4GBq
Study: NCT05395208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic touch group accompanied by white noise
Description: During the intravenous catheter intervention, approximately 15-20 minutes of white noise was applied with therapeutic touch.
Study: NCT06226025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants randomized to this intervention will take 1 oral pill (0.5 milligrams (mg)) daily. They will attend 4 weekly behavioral sleep intervention sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to this intervention will take 1 oral placebo pill daily. They will attend 4 weekly behavioral sleep control sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Description: An active intervention that is typically paired with melatonin to maximize treatment effects.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral sleep control
Description: A behavioral placebo (which does not improve sleep in delayed sleep-wake phase disorder) to control for social/interpersonal effects of behavioral sleep intervention sessions.
Study: NCT05525676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Relationship Checkup (BRC)
Description: The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status.
Study: NCT05322161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga classes
Description: There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~1. Yoga postures (Asana) = low impact gentle postures meant to be done individually~2. Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~3. Meditation (Dhyana) = guided meditation
Study: NCT05525676

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Co-Located Collaborative Care (CCC)
Description: The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 \& 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)
Study: NCT05841524

Intervention type: DIAGNOSTIC_TEST
Intervention: Vector flow imaging measurement
Description: Ultrasound measurement, using high framerate measurement techniques.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vector flow imaging measurement
Description: Ultrasound measurement, using high framerate measurement techniques.
Study: NCT05267600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral Prednisone
Study: NCT06472024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Verum Acupuncture
Description: Acupuncture therapy uses filiform needles at a perpendicular angle at acupuncture points to produce a therapeutic effect.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham Acupuncture therapy uses filiform needles but is only attached with tape to acupuncture points
Study: NCT04705233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sputum colour chart
Description: 5-point Sputum Colour Chart plus best standard care
Study: NCT06548516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group (conventional scalpel surgery)
Description: The patients in the control group will undergo frenectomy using conventional scalpel surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser group
Description: The patients in the laser group will undergo frenectomy using a diode laser.
Study: NCT06296355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Warning Label
Description: Message displayed on warning label is: WARNING: Consuming ultra-processed food and drinks can cause weight gain, which increases the risk of obesity and type 2 diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity Warning Label
Description: Message displayed on warning label is: WARNING: Ultra-processed food.

Intervention type: OTHER
Group type: OTHER
Intervention: Barcode Label
Description: Barcode is displayed.
Study: NCT03999853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKR-017
Description: BKR-017
Study: NCT06051214

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: thrombogram
Description: blood sampling every month for 12 months
Study: NCT06310694

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intervention group (Elastane circular dressing on sterile transparent dressing)
Description: A circular dressing made of elastane material was placed on the patients in the intervention group on a sterile transparent dressing to provide additional fixation on the peripheral intravenous catheter.
Study: NCT04802109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing level D personal protective equipment
Description: rubber gloves + surgical face mask + general isolation clothing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing level D personal protective equipment
Description: rubber gloves + surgical face mask + general isolation clothing

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wearing level D personal protective equipment
Description: rubber gloves + surgical face mask + general isolation clothing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing Level C personal protective equipment with N-95
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing Level C personal protective equipment with N-95
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wearing Level C personal protective equipment with N-95
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing Level C personal protective equipment with Powered Air-Purifying Respiratory
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing Level C personal protective equipment with Powered Air-Purifying Respiratory
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wearing Level C personal protective equipment with Powered Air-Purifying Respiratory
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory
Study: NCT06569472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targetd CAR-T
Description: Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion
Study: NCT06571916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief-SfSL
Description: Brief-SfSL is a single 90-minute intervention that that:~1. helps clients understand their suicide narrative, which explores the origin and meaning of their suicidal thoughts~2. builds specific skills to keep oneself safe from suicide even if suicidal thoughts are present~3. includes enhanced safety planning by identifying the barriers to enacting a safety plan and solutions to overcome them
Study: NCT06572020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: simulation-based training on blood pressure and ECG measurement
Study: NCT06570616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP (fixed mode)
Description: Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APAP (automatic mode)
Description: Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
Study: NCT06289582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]DPA714 administration IV
Description: brain PET/MRI imaging after \[F-18\]DPA-714 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]DPA714 administration IV
Description: brain PET/MRI imaging after \[F-18\]DPA-714 administration